Cost-effectiveness analysis of FOLFIRINOX vs gemcitabine with nab-paclitaxel as adjuvant treatment for resected pancreatic cancer in the United States based on PRODIGE-24 and APACT trials

BACKGROUND: Pancreatic cancer is associated with low median overall survival. Combination chemotherapy regimens FOLFIRINOX and gemcitabine with nab-paclitaxel (GemNab) are the new adjuvant treatment standards for resectable pancreatic cancer. PRODIGE-24 and APACT trials demonstrated superior clinica...

Descripción completa

Detalles Bibliográficos
Autores principales: Kharat, Aditi A, Nelson, Richard, Au, Trang, Biskupiak, Joseph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391115/
https://www.ncbi.nlm.nih.gov/pubmed/34595948
http://dx.doi.org/10.18553/jmcp.2021.27.10.1367

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391115/
https://www.ncbi.nlm.nih.gov/pubmed/34595948
http://dx.doi.org/10.18553/jmcp.2021.27.10.1367

Ejemplares similares